Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.63 |
| ▸ | PI4KA | P42356 | 2/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.59 |
| ▸ | AHCY | P23526 | 5/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421178 | 0.85 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10015788 | 0.84 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1249908 | 0.84 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10882488 | 0.84 | ADORA2A (0.63) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10878427 | 0.84 | ADORA2A (0.65) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL336404 | 0.84 | ADORA2A (0.65) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL599463 | 0.83 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1635108 | 0.82 | CCNE1 (0.60) | ADORA2AADORA1AHCY | |
| SCHEMBL23547672 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22855519 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5627165-A | ANTIVIRAL AND ANTILEUKEMIA AGENTS | DRUG INNOVATION & DESIGN, INC. (US) | 1997-05-06 | — | — | US | claimed |
| WO-1992016212-A1 | INCREASING THE THERAPEUTIC EFFICIENCY OF MACROPHAGE-TARGETED THERAPEUTIC AGENTS BY UP-REGULATING THE MANNOSE LECTIN ON MACROPHAGES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-10-01 | — | — | WO | claimed |
| EP-4019048-A1 | ABCC11 INHIBITOR | The University of Tokyo (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-9932646-B2 | Detection and use of antiviral resistance mutations | ABL SA (LU) | 2018-04-03 | — | — | US | disclosed |
| US-9702005-B2 | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof | ABL SA (LU) | 2017-07-11 | — | — | US | disclosed |
| US-9701982-B2 | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof | ABL SA (LU) | 2017-07-11 | — | — | US | disclosed |
| US-9682109-B2 | Antiviral resistance mutants and applications thereof | ABL SA (LU) | 2017-06-20 | — | — | US | disclosed |
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| WO-2016123504-A1 | BTK INHIBITOR COMBINATIONS AND MULTIDRUG-RESISTANCE | PHARMACYCLICS LLC (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160032410-A1 | DETECTION AND USE OF ANTIVIRAL RESISTANCE MUTATIONS | BARTHOLOMEUSZ ANGELINE INGRID (AU) | 2016-02-04 | — | — | US | disclosed |
| EP-2980095-A1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.Leuven Research & Development (BE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2002003993-A2 | USE OF INHIBITORS TO MULTIDRUG RESISTANCE PROTEIN 5 (MRP5) TO ENHANCE INTRACELLULAR LEVELS OF CYCLIC NUCLEOTIDES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2002-01-17 | — | — | WO | disclosed |
| EP-1003762-A2 | BASE ANALOGUES | Nycomed Amersham PLC (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006422-A2 | BASE ANALOGUES | NYCOMED AMERSHAM PLC (GB) | 1999-02-11 | — | — | WO | disclosed |
| US-5760022-A | ESTER, ETHER | PERSTORP AB (SE) | 1998-06-02 | — | — | US | disclosed |
| EP-0797443-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIO-AVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1997-10-01 | — | — | EP | disclosed |
| US-5614510-A | AMMONIUM SALTS | PERSTORP AB (SE) | 1997-03-25 | — | — | US | disclosed |
| WO-1995019775-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIO-AVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1995-07-27 | — | — | WO | disclosed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | disclosed |
| WO-1992016212-A1 | INCREASING THE THERAPEUTIC EFFICIENCY OF MACROPHAGE-TARGETED THERAPEUTIC AGENTS BY UP-REGULATING THE MANNOSE LECTIN ON MACROPHAGES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-10-01 | — | — | WO | disclosed |